SITE Centers Corp.(SITC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SITC SITE Centers Corp.

Closed 11-15 16:00:00 EST

15.62

-0.14

-0.89%

盘后15.62

+0.000.00%

18:45 EST

High15.84	Low15.52	Vol961.77K
Open15.84	D1 Closing15.76	Amplitude2.03%
Mkt Cap818.34M	Tradable Cap747.36M	Total Shares52.39M
T/O15.02M	T/O Rate2.01%	Tradable Shares47.85M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"SITC","market":"US","secType":"STK","nameCN":"SITE Centers Corp.","latestPrice":15.62,"timestamp":1731704400000,"preClose":15.76,"halted":0,"volume":961768,"hourTrading":{"tag":"盘后","latestPrice":15.62,"preClose":15.62,"latestTime":"18:45 EST","volume":21681,"amount":338657.22,"timestamp":1731714318640},"delay":0,"floatShares":47846400,"shares":52390515,"eps":8.527446,"marketStatus":"Closed","change":-0.14,"latestTime":"11-15 16:00:00 EST","open":15.84,"high":15.84,"low":15.52,"amount":15016737.78624,"amplitude":0.020305,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":8.527446,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1731920400000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":15.76,"aum":0,"dividendRate":0.099872,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":15.75,"preClose":15.76,"latestTime":"09:27 EST","volume":1,"amount":15.75,"timestamp":1731680879551},"postHourTrading":{"tag":"盘后","latestPrice":15.62,"preClose":15.62,"latestTime":"18:45 EST","volume":21681,"amount":338657.22,"timestamp":1731714318640},"volumeRatio":0.794662,"impliedVol":0.0508,"impliedVolPercentile":0.0717},"requestUrl":"/m/hq/s/SITC/wiki","defaultTab":"wiki","newsList":[{"id":"2483332231","title":"Press Release: Akoya Biosciences Reports Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483332231","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483332231?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:00","pubTimestamp":1731618000,"startTime":"0","endTime":"0","summary":"MARLBOROUGH, Mass., Nov. 14, 2024  -- Akoya Biosciences, Inc.  , The Spatial Biology Company, today announced its financial results for the third quarter ending September 30, 2024.\"Our third-quarter results came in below expectations, largely due to ongoing capital equipment purchase constraints seen across the life science tools market. We remain optimistic about the long-term growth outlook of our industry, but we recognize the current environment will pose temporary challenges. We proactively anticipated this with our recent organizational restructuring, which, while difficult and temporarily disruptive this quarter, was the right decision and enhanced our readiness to absorb the headwinds we are facing,\" said Brian McKelligon, CEO of Akoya Biosciences. \"We remain confident that Akoya's technologies will continue to be the preferred platform in the spatial biology market from discovery to diagnostics, supporting a return to topline growth in 2025, and beyond, and achievement of our ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","BK4231","SITC","BK4232","03160","R","BK4099","BK4022","TM","BK4585","AKYA","BK4080","BK4588"],"gpt_icon":0},{"id":"2483178806","title":"Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2483178806","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483178806?lang=en_us&edition=fundamental","pubTime":"2024-11-14 22:00","pubTimestamp":1731592800,"startTime":"0","endTime":"0","summary":"Emerging leadership in allogeneic CAR-T for hematologic malignancies demonstrated by recent P-BCMA-ALLO1 Phase 1 data and new preclinical findings for P-CD19CD20-ALLO1 and P-CD70-ALLO1. Latest preclinical data on P-BCMACD19-ALLO1 demonstrates its potential as a next-generation allogeneic TSCM-rich CAR-T for both autoimmune diseases and oncology. Advancing innovative strategies to overcome the unique challenges of applying CAR-T to solid tumors. SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. , a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced plans to share progress across its clinical- and earlier-stage pipeline of differentiated T stem cell memory cells -rich allogeneic CAR-T therapies in oncology and autoimmune diseases during a virtual R&D Day to be held today at10:00am ET/7:00am PT.The event will feature presentations by mem","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0ZbecZcTygdfn10jwwgw3w--~B/aD0yOTA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/4f05f1549db26db37f15a45f2f462010","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0ZbecZcTygdfn10jwwgw3w--~B/aD0yOTA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/4f05f1549db26db37f15a45f2f462010"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/poseida-therapeutics-hosts-cell-therapy-140000681.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/poseida-therapeutics-hosts-cell-therapy-140000681.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0267386448.USD","BK4504","BK4516","LU1720051108.HKD","BK4080","LU0106831901.USD","BK4534","LU1363072403.SGD","LU1989772840.SGD","BK4077","BK4581","LENZ","LU0106261372.USD","LU1162221912.USD","LU0320765646.SGD","LU0314104364.USD","LU0006306889.USD","LU0971096721.USD","LU1548497426.USD","BK4139","LU2357305700.SGD","IE00BKVL7J92.USD","LU1668664300.SGD","SLE","LU0098860793.USD","LU1074936037.SGD","BK4585","SITC","BK4231","BK4588","BK4022","CAR","BK4230","PSTX","RA","IE00BZ1G4Q59.USD","LU1720051017.SGD","BK4127","LU0225283273.USD","LU1989772923.USD"],"gpt_icon":0},{"id":"2483887749","title":"Biotech and Medical Tech Stocks Report Significant Updates in the Race for Cancer Treatments as Cancer Rates Rise Globally","url":"https://stock-news.laohu8.com/highlight/detail?id=2483887749","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483887749?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:00","pubTimestamp":1731589200,"startTime":"0","endTime":"0","summary":"Vancouver, Kelowna, and Delta, British Columbia-- - Investorideas.com, a go-to investing platform covering biotech and medical technology stocks releases a snapshot looking at the advancement of treatments for solid tumors as global cancer incidence rates rise, featuring Aethlon Medical, Inc. , a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.Looking at the harsh reality of the rise of cancer globally, the BBC reported earlier this year, \"One study found that the global incidence of early-onset cancer had increased by 79% between 1990 and 2019, with the number of cancer-related deaths in younger people rising by 29%. Another report in The Lancet Public Health described how cancer incidence rates in the US have steadily risen between the generations across 17 different cancers, particularly in Generation Xers and Millennials.\". Yesterday, Aethlon Medical, Inc.  reported financial results for its fiscal second quarter e","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/yvTTJD_651JhC3eRbd.HuQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/f6dccb4b99c4df8559d8017528792388","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/yvTTJD_651JhC3eRbd.HuQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/f6dccb4b99c4df8559d8017528792388"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/biotech-medical-tech-stocks-report-130000783.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-medical-tech-stocks-report-130000783.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1854103824.USD","BK4583","IE00BZ199S13.USD","LU1720051108.HKD","ON","LU1861220033.SGD","LU2357305700.SGD","CAR","BK4230","IE00BD6J9T35.USD","BK4512","LU1548497426.USD","LU1861214812.USD","CTOS","LU1978683503.SGD","BK4159","IE00B66KJ199.SGD","CAGR","SITC","LU2298322129.HKD","BK4231","BK4104","BK4022","LU1861215975.USD","BK4568","IE00B19Z4B17.USD","BK4080","BK4006","LU1720051017.SGD","BK4141","IE0031619046.USD","IE00B7SZL793.SGD","LU2360107325.USD","BK4585","BK4588","LU1861219969.SGD","AEMD","LU0724618433.USD","LU0348723411.USD","LU0124384867.USD","CRS","BK4082","LU1854104046.USD"],"gpt_icon":1},{"id":"2483808091","title":"TriSalus Reports Q3 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483808091","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483808091?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:00","pubTimestamp":1731589200,"startTime":"0","endTime":"0","summary":"– Reported Q3 and nine-month revenues of $7.3 million and $21.2 million respectively, up 42% and 66% year-over-year. – Provided 2025 guidance with expectations of over 50% annual sales growth, 20%+ reduction in operating expenses, positive full-year EBITDA, and positive cash flow in H2 2025. – Launched TriNav LV Infusion System and TriGuide Guiding Catheter for larger vessels and complex cases, expanding the TriNav system’s full access to the $375 million embolization market. – Initiated the PROTECT registry trial using the TriNav system to treat multinodular goiters, expanding the TriNav system’s reach into the $400 million thyroid embolization market. – Presented positive Phase 1 data from PERIO-01 trial in patients with uveal melanoma with liver metastases  at the Society for Immunotherapy of Cancer  meeting and announced the strategic decision to seek a partner to drive further development of this indication. \"Finally, we are initiating 2025 guidance that calls for greater than 50%","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/SkMr7LXEipySTNpLmR3rEg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/64005b3f85c23a135c84a7cf7fd07d72","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/SkMr7LXEipySTNpLmR3rEg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/64005b3f85c23a135c84a7cf7fd07d72"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/trisalus-reports-q3-2024-financial-130000132.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TLSIW","SITC","BK4231","TLSI","BK4080"],"gpt_icon":0},{"id":"2483987146","title":"Press Release: Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2483987146","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483987146?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:30","pubTimestamp":1731587400,"startTime":"0","endTime":"0","summary":"- SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 -. - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 -. \"The third quarter of 2024 saw significant progress in advancing patient enrollment in the dose expansion portion of the Phase 1 study for SNS-101 across dose levels and patients with primary and acquired resistance to PD-1 inhibitors. Looking ahead, management has focused its attention on preparing for Phase 2 studies,\" said John Celebi, President and Chief Executive Officer. \"We believe SNS-101 has disruptive potential for the treatment of a multitude of cancer indications and for this reason we are making the difficult decision to reduce our headcount to focus our resources on advancing the clinical development of SNS-101. We anticipate that these changes will extend our cash runway into the second quarter of 2026. We look forward to sharing a clinical update focused primarily on the activity prof","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4555","SITC","BK4080","BK4099","BK4588","03160","BK4231","R","SNSE","TM","BK4585","BK4232","BK4022"],"gpt_icon":0},{"id":"2483876246","title":"MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483876246","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483876246?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:00","pubTimestamp":1731585600,"startTime":"0","endTime":"0","summary":"NEW YORK, Nov.  14, 2024  (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc.(NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogene","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/14/2981009/0/en/MiNK-Therapeutics-Reports-Third-Quarter-2024-Results-and-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","INKT","BK4080","BK4139","SITC","LENZ"],"gpt_icon":1},{"id":"2483863367","title":"Adaptimmune Reports Q3 2024 Financial and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483863367","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483863367?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:05","pubTimestamp":1731531900,"startTime":"0","endTime":"0","summary":"Tecelra launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient apheresed in Q3; expect first commercial revenues in Q4 and the number of treated patients to accelerate throughout 2025. Lete-cel IGNYTE-ESO pivotal trial primary analysis reports 42% overall response rate in synovial sarcoma and myxoid/round cell liposarcoma ; full data at CTOS conference on November 16. Company restructuring to prioritize commercial sarcoma franchise and R&D programs with highest potential return on invested capital and transformational benefit to patients. Planned 33% reduction in headcount in Q1, 2025 as part of approximately $300 million in aggregate cost savings over the next four years enables company to target an operating breakeven during 2027. At the end of Q3, Adaptimmune had Total Liquidity1 of $186.1 million. Adaptimmune's collaboration with Galapagos is underway, and plans are progressing to conduct a clinical proof-of-concep","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7mLBbBwlKtSoTxTWXmNO3Q--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/fbd07c7f19dd3e862ab92febbb00adbf","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7mLBbBwlKtSoTxTWXmNO3Q--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/fbd07c7f19dd3e862ab92febbb00adbf"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/adaptimmune-reports-q3-2024-financial-210500342.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adaptimmune-reports-q3-2024-financial-210500342.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADAP","BK4139","BK4104","CTOS","BK4231","SITC","BK4080"],"gpt_icon":1},{"id":"2483673883","title":"Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483673883","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483673883?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:30","pubTimestamp":1731504600,"startTime":"0","endTime":"0","summary":"Establishing growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value oncology indications. Ongoing progress towards first in human clinical study for locally advanced or metastatic solid tumors. Strategic focus on exploratory investigator-initiated studies with institutional partners. FRAMINGHAM, MA / ACCESSWIRE / November 13, 2024 / Xenetic Biosciences, Inc.  , a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the third quarter of 2024.\"Over the course of the past quarter, we have continued to make progress advancing our DNase platform. Our focus is to leverage institutional partnerships to drive our development strategy, such as our recently announced agreement with Tokyo Medical University and extension of our agreement with The Scripps Research Institute, efficiently utilizing our capital while minimizing our non-progr","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fM5fYtWf.tghhggjYXtYVA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/e084a05152e8afc9376f13e005f562b9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fM5fYtWf.tghhggjYXtYVA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/e084a05152e8afc9376f13e005f562b9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xenetic-biosciences-inc-reports-third-133000783.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4080","XBIOW","XBIO","BK4231","BK4139","SITC"],"gpt_icon":0},{"id":"2483006933","title":"Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2483006933","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483006933?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:00","pubTimestamp":1731499200,"startTime":"0","endTime":"0","summary":"Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma. Candidate nominations for IL-18 and IL-12 programs expected in Q4 2024, and IND submission for Mural’s IL-18 program planned for Q4 2025. Mural reiterates guidance on projected cash runway into Q4 2025. WALTHAM, Mass. and DUBLIN, Nov. 13, 2024  -- Mural Oncology plc , a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced financial results for the third quarter of 2024 and provided an update on pipeline progress.Completion of enrollment in ARTISTRY-6, Cohort 2, the company’s potentially registrational phase 2 study of single agent nemvaleukin in patients with unresectable or metastatic mucosal melanoma, with 92 patients enroll","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/mtrZ7S0S1V9C_hT3L2QLmQ--~B/aD04ODt3PTg4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/23237569ce0500cf957b557e72cbd3bd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/mtrZ7S0S1V9C_hT3L2QLmQ--~B/aD04ODt3PTg4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/23237569ce0500cf957b557e72cbd3bd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mural-oncology-announces-third-quarter-120000973.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PRGS","OS","PROC","BK4231","LU2065732104.USD","BK4097","MURA","BK4139","BK4007","SITC","BK4080"],"gpt_icon":0},{"id":"2483726049","title":"Press Release: Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483726049","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483726049?lang=en_us&edition=fundamental","pubTime":"2024-11-13 14:00","pubTimestamp":1731477600,"startTime":"0","endTime":"0","summary":"Jonathan Dickinson appointed Chief Executive Officer and Chairman of. Encouraging initial FDA feedback received on lacutamab regulatory. Lacutamab health-related quality of life and translational data to be. IPH4502, a Nectin-4 ADC received FDA clearance of the IND to be. Preclinical data for proprietary tetra-specific NK cell engager IPH6501. Cash position of EUR96.4 million1 as of September 30, 2024, anticipated. Innate Pharma SA   today announced its business update and financial results for the first nine months of 2024.found on the Investors section of the Innate Pharma website,www.innate-pharma.com. A replay of the webcast will be available on the. TELLOMAK is a global, open-label, multi-cohort Phase 2 clinical trial evaluating lacutamab in patients with Sézary syndrome and mycosis fungoides.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPHA","BK4080","BK4022","R","BK4139","BK4109","SITC","BK4231","BK4232","ASH","LU2463526074.USD","CRT","IPHYF","BK4213","ADC"],"gpt_icon":0},{"id":"2483069317","title":"Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483069317","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483069317?lang=en_us&edition=fundamental","pubTime":"2024-11-13 06:29","pubTimestamp":1731450540,"startTime":"0","endTime":"0","summary":"Announced FDA Clearance of the Northwestern University IND Application for NeuroNova (CLD-101) Clinical Trial in High-Grade Glioma.Presented data supporting RTNova (CLD-400), the company’s systemic an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/12/2979819/0/en/Calidi-Biotherapeutics-Reports-Third-Quarter-2024-Operating-and-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","SITC","BK4231"],"gpt_icon":0},{"id":"2483805717","title":"Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483805717","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483805717?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:05","pubTimestamp":1731445500,"startTime":"0","endTime":"0","summary":"Advanced to the highest dose level in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancers. Presented updated preclinical activity of BDC-4182 and key learnings from Phase 1 dose-escalation trial of BDC-1001 at the SITC 39th Annual Meeting. BDC-4182 on track to start clinical trial in second quarter 2025. Cash balance of $84.4 million as of September30, 2024 anticipated to fund key milestones through mid-2026. Presented key learnings from Phase 1 dose-escalation trial of BDC-1001 at SITC. First-generation ISAC BDC-1001 demonstrated immunological activity in this first-in-human trial, particularly in patients with high HER2 antigen expression. Greater immune activation appeared to be associated with clinical benefit. Pharmacodynamic changes were observed in","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/WQnjrpSE64RGghUY6gHtIg--~B/aD03NDt3PTE2NjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/4f2bcc04958da8749e43c265cdf66641","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/WQnjrpSE64RGghUY6gHtIg--~B/aD03NDt3PTE2NjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/4f2bcc04958da8749e43c265cdf66641"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bolt-biotherapeutics-reports-third-quarter-210500732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SITC","BK4139","BOLT","BK4080","BK4231"],"gpt_icon":0},{"id":"2483050810","title":"Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2483050810","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483050810?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:05","pubTimestamp":1731445500,"startTime":"0","endTime":"0","summary":"Portfolio Prioritization and Corporate Restructuring Extends Cash Runway into 2Q 2026SAN DIEGO, Nov.  12, 2024  (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TS","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/12/2979706/0/en/Turnstone-Biologics-Corp-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Recent-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","TSBX","BK4505","TIL","BK4139","BK4231","SITC"],"gpt_icon":0},{"id":"2483050346","title":"Singular Genomics Reports Recent Updates and Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483050346","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483050346?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:05","pubTimestamp":1731445500,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Nov.  12, 2024  (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empowe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/12/2979683/0/en/Singular-Genomics-Reports-Recent-Updates-and-Third-Quarter-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","BK4080","NGS","SITC","BK4179"],"gpt_icon":0},{"id":"2482470695","title":"CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2482470695","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482470695?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:20","pubTimestamp":1731414000,"startTime":"0","endTime":"0","summary":"Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter. 400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to 551 million; expected cash runway re-affirmed into 2028. CVGBM Phase 1 glioblastoma study showed 77% of patients with antigen-specific T-cell responses; data presented at ESMO, SITC and SNO. New off-the-shelf program for squamous non-small cell lung cancer started, expected to enter Phase 1 in H2 2025. New preclinical prophylactic vaccine program for urinary tract infections initiated, supported by positive preclinical data versus protein-based vaccines. Positive Phase 2 data from seasonal influenza program licensed to GSK demonstrated strong immune responses against challenging influenza B as well as A strains; program progressing to Phase 3, which will be associated with significant milestone payment. Corporate redesign on track with 30% workforce reduction, expected to yield signi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bx7cdeRNxEwazNcDWucEIw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/a0ea1b5efd3fe31259aaba2e79e18980","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bx7cdeRNxEwazNcDWucEIw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/a0ea1b5efd3fe31259aaba2e79e18980"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/curevac-announces-financial-results-third-122000623.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4231","BK4548","CVAC","BK4080","SITC","CTA","CMO","BK4551","BK4139"],"gpt_icon":1},{"id":"2482570824","title":"Press Release: IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2482570824","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482570824?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:05","pubTimestamp":1731413100,"startTime":"0","endTime":"0","summary":"therapeutic cancer vaccine IO102-IO103 in combination with Merck's. melanoma on track with primary endpoint of progression free survival.  projected to be reached in first half of 2025. -- Primary endpoint met in Phase 2 basket trial  cohort. evaluating IO102-IO103 in combination with pembrolizumab in the. first-line treatment of advanced squamous cell carcinoma of the head and. treatment of patients with resectable melanoma or SCCHN is proceeding. equivalents; the company continues to expect its cash position will. support operations into the fourth quarter of 2025. Dr. Zocca continued, \"Our T-win platform generates off-the-shelf therapeutic cancer vaccine candidates with a unique mechanism of action, capable of both targeting immune-suppressive cells and cancer cells. This dual action is what drives the strong activity we see when we combine IO102-IO103 with an anti-PD-1 therapy. In addition to IO102-IO103, the T-win platform has generated other novel candidates including IO112, targ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0265550359.USD","LU1037948897.HKD","LU1066053197.SGD","BK4526","BK4533","IE00BLSP4239.USD","LU0965509101.SGD","LU0320765489.SGD","MRK","BK4559","BK4550","LU1934455277.USD","LU0266013472.USD","IO","IE00BFTCPJ56.SGD","IE00BYTNYN87.SGD","BK4548","BK4571","01698","IE000M9KFDE8.USD","IE0009355771.USD","R","IE00BBT3K403.USD","LU2039709279.SGD","PFS","LU1934455863.HKD","BK4195","IE00B2B36J28.USD","BK4231","IE00BLSP4452.SGD","LU1093756168.USD","LU1116320901.HKD","IE00BSNM7G36.USD","LU1061106388.HKD","BK4108","LU1585245621.USD","LU1093756325.SGD","LU0211331839.USD","IOBT","LU1066051498.USD","BK4022","SITC","DRR","LU1037948541.HKD","OS","LU0208291251.USD","LU0238689110.USD","TME","LU0058720904.USD"],"gpt_icon":0},{"id":"2482765512","title":"Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2482765512","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482765512?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:05","pubTimestamp":1731359100,"startTime":"0","endTime":"0","summary":"Revenues increased 17% compared to the previous quarter ended June 30, 2024. Strengthened balance sheet is expected to provide sufficient cash runway through June 2026. Completed a $20.6 million private placement offering with multiple healthcare-focused institutional funds and Company insiders. Retired $17.5 million in debt from Avenue Capital and entered into a $11.5 million loan agreement with an insider-led investor group. Conference call scheduled for 4:30 p.m. ET today, November 11th. Lisi added: “Our executive team and board of directors have taken decisive actions this year to enhance the Company’s financial health and commercial execution as we continue accelerating our revenue growth. We recently implemented a capital conservation strategy to preserve cash, executed a series of financial transactions that increased our capital resources and eliminated approximately $12 million in debt-related payments through mid-2026. We are confident that these strategic initiatives, in con","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/QgRx4xT.lDlZwhWdU9QtvQ--~B/aD01MDt3PTI2NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/6a300ee43d00bd4b0b0022a6aa54de1d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/QgRx4xT.lDlZwhWdU9QtvQ--~B/aD01MDt3PTI2NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/6a300ee43d00bd4b0b0022a6aa54de1d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beyond-air-reports-fiscal-second-210500605.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4231","BK4588","BK4585","WRD","BK4080","SITC","AIRI","XAIR","BK4178","BK4082","BK4187"],"gpt_icon":0},{"id":"2482356257","title":"Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2482356257","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482356257?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:45","pubTimestamp":1731332700,"startTime":"0","endTime":"0","summary":"Study, in patients with solid tumors focusing on gynecological malignant tumors such as ovarian, endometrial, and cervical, nearing completion with three remaining subjects to be enrolled. 33% Clinical Benefit Rate  with a median Progression Free Survival  of 57 weeks. The trial is being conducted by Haider Mahdi, M.D., Assistant Professor, Department of Obstetrics, Gynecology & Reproductive Sciences, at the University of Pittsburgh. The study aims to identify an optimal dose for future trials and explore the impact of a treatment regimen combining pembrolizumab and LYMPHIR on the tumor immune microenvironment.\"We have seen promising results in patients with heavily pre-treated recurrent or metastatic gynecologic tumors and will enroll three additional patients before completing the Phase I portion of this study,\" said Mahdi. \"We will further investigate in patients with gynecologic tumors and those with other solid tumor histologies. We want to explore the impact of this therapy on Tr","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/lyzveXqzu4d1PfNj1ia_vQ--~B/aD0yMDE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/b9fff1eac44814237bf8b5b5f3339441","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/lyzveXqzu4d1PfNj1ia_vQ--~B/aD0yMDE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/b9fff1eac44814237bf8b5b5f3339441"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/citius-pharmaceuticals-inc-citius-oncology-134500290.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/citius-pharmaceuticals-inc-citius-oncology-134500290.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0289739699.SGD","LU1116320901.HKD","LU0058720904.USD","IE000M9KFDE8.USD","LU0208291251.USD","PFS","IE0002141913.USD","BK4145","IE00BFTCPJ56.SGD","LU0234572021.USD","LU1934455277.USD","LU1037948541.HKD","LU0266013472.USD","PR","IE00B2B36J28.USD","IE00B1BXHZ80.USD","CLS","LU0965509101.SGD","LU1023059063.AUD","LU1057294990.SGD","SITC","BK4550","BK4007","BK4585","LU0106261372.USD","LU0265550359.USD","LU0006306889.USD","LU0965509283.SGD","BK4080","IE00BLSP4239.USD","LU0122379950.USD","BK4195","LU1066053197.SGD","BK4231","LU1941712264.USD","LU0238689110.USD","LU0203347892.USD","LU0320765489.SGD","LU0211331839.USD","LU1934455863.HKD","MRK","BK4559","LU0265550946.USD","IE00BSNM7G36.USD","IE0009355771.USD","BK4533","CTXR","LU1934455194.USD","LU1291159041.SGD"],"gpt_icon":0},{"id":"2482860377","title":"BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2482860377","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482860377?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:00","pubTimestamp":1731330000,"startTime":"0","endTime":"0","summary":"In 30 metastatic NSCLC patients who progressed on PD-1/PD-L1 inhibitors, the triple IO combo regimen at median follow-up time of 11.5 months achieved a DCR of 89.3% and Median PFS of 8.6 months. FLORHAM PARK, N.J., Nov. 11, 2024  -- BeyondSpring Inc.  , a clinical-stage global biopharmaceutical company developing innovative cancer therapies, today announced that phase 2 IIT  data on the first 30 patients dosed with plinabulin in the 303 Study of patients with non-small cell lung cancer  after disease progression on PD-1/PD-L1 inhibitors with and without chemotherapy were presented at the 39th Society for Immunotherapy of Cancer's  Annual Meeting on November 8th, 2024 in Houston, Texas.Docetaxel remains the standard of care for patients with 2L/3L NSCLC without targetable alterations who progress on immune checkpoint inhibitors  with and without standard chemotherapy. In the recent TROPION Lung-01 phase 3 studies, a similar patient population had an overall response rate  of 12.8% and m","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/PTfY5oONQfPzPeh5YxE1pQ--~B/aD04OTt3PTI1NTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/2252d7f4e6919c4cae951939c4d7ae1d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/PTfY5oONQfPzPeh5YxE1pQ--~B/aD04OTt3PTI1NTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/2252d7f4e6919c4cae951939c4d7ae1d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beyondspring-presents-updated-efficacy-results-130000539.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0053666078.USD","IO","LU0157215616.USD","LU1366333091.USD","BK4588","LU2236285917.USD","LU2237443382.USD","LU1366192091.USD","L","BK4107","LU2417539215.USD","BK4179","SITC","LU2456880835.USD","BYSI","WRD","LU2420271590.USD","LU2237443549.SGD","BK4563","LU0077335932.USD","BK4231","APC","BK4080","LU2237443622.USD","BK4139","BK4585","LU2237443978.SGD"],"gpt_icon":0},{"id":"2482786051","title":"CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2482786051","media":"GlobeNewswire","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482786051?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:00","pubTimestamp":1731330000,"startTime":"0","endTime":"0","summary":"– Phase 1b study results were published simultaneously in Nature Medicine and presented at the Society for Immunotherapy of Cancer 2024 –。– Encouraging data adds to the body of evidence supporting potential use of cretostimogene as a backbone bladder-sparing therapeutic for bladder cancer –。This is the second publication in Nature Medicine evaluating the safety and efficacy of cretostimogene grenadenorepvec this year. In June 2024, Nature Medicine published the final results from CORE-001, a phase 2 study of cretostimogene grenadenorepvec in combination with another checkpoint inhibitor, pembrolizumab, in high-risk Bacillus Calmette Guerin -unresponsive non-muscle invasive bladder cancer .About the Phase 1b StudyThe Phase 1b study examined the safety and efficacy of combining cretostimogene grenadenorepvec with nivolumab in patients with MIBC who were ineligible for cisplatin chemotherapy. Of the 21 patients enrolled and treated, there were no dose-limiting toxicity and no grade 3 or h","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/PGAn7Ub.kbtQmM44hCDcNw--~B/aD0xOTE7dz0xMTI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/15e379d5feda7db9477b0d6dfc1496ab","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/PGAn7Ub.kbtQmM44hCDcNw--~B/aD0xOTE7dz0xMTI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/15e379d5feda7db9477b0d6dfc1496ab"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cg-oncology-announces-nature-medicine-130000011.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TRAE","CGON","BK4135","CG","SITC","BCG","WRD","BK4080","IE00B64PRP62.GBP","BK4231","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sitecenters.com","stockEarnings":[{"period":"1week","weight":-0.0101},{"period":"1month","weight":-0.0858},{"period":"3month","weight":-0.7435},{"period":"6month","weight":-0.7252},{"period":"1year","weight":-0.7017},{"period":"ytd","weight":-0.7109}],"compareEarnings":[{"period":"1week","weight":-0.0038},{"period":"1month","weight":0.0234},{"period":"3month","weight":0.0704},{"period":"6month","weight":0.1207},{"period":"1year","weight":0.3195},{"period":"ytd","weight":0.2483}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"SITE Centers is an owner and manager of open-air shopping centers located in suburban, high household income communities. The Company is a self-administered and self-managed REIT operating as a fully integrated real estate company, and is publicly traded on the New York Stock Exchange under the ticker symbol SITC.","yearOnYearQuotes":[{"month":1,"riseRate":0.483871,"avgChangeRate":0.001442},{"month":2,"riseRate":0.6,"avgChangeRate":0.009342},{"month":3,"riseRate":0.65625,"avgChangeRate":-0.00021},{"month":4,"riseRate":0.5625,"avgChangeRate":0.032159},{"month":5,"riseRate":0.4375,"avgChangeRate":0.000981},{"month":6,"riseRate":0.75,"avgChangeRate":0.022019},{"month":7,"riseRate":0.65625,"avgChangeRate":0.015994},{"month":8,"riseRate":0.46875,"avgChangeRate":0.00249},{"month":9,"riseRate":0.46875,"avgChangeRate":-0.015322},{"month":10,"riseRate":0.4375,"avgChangeRate":-0.04178},{"month":11,"riseRate":0.46875,"avgChangeRate":0.001838},{"month":12,"riseRate":0.645161,"avgChangeRate":0.015755}],"exchange":"NYSE","name":"SITE Centers Corp.","nameEN":"SITE Centers Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SITE Centers Corp.(SITC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest SITE Centers Corp.(SITC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"SITE Centers Corp.,SITC,SITE Centers Corp.股票,SITE Centers Corp.股票老虎,SITE Centers Corp.股票老虎国际,SITE Centers Corp.行情,SITE Centers Corp.股票行情,SITE Centers Corp.股价,SITE Centers Corp.股市,SITE Centers Corp.股票价格,SITE Centers Corp.股票交易,SITE Centers Corp.股票购买,SITE Centers Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SITE Centers Corp.(SITC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest SITE Centers Corp.(SITC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction